re: Ann: Appendix 4C - Quarter Ended 30 Septe... this one is on my watchlist. not unlike other aussie biotechs it has had some recent difficulties the the fda. only holds enough cash for next 2 quarters. directors will be getting a little titchy. are there any payments such as a tax rebate expected in next short while? am i correct in my assessment that fda is very likely to give marketing authority?
